A historic medical precedent has been recorded in the Mykolaiv region: a female cancer patient has received a modern medicinal product based on medical cannabis for the first time via an electronic prescription. The drug was prescribed by specialists at the municipal non-profit enterprise 'Mykolaiv Regional Oncology Center', and the medication was dispensed by the 'Pharmacia' enterprise. This event marks an important milestone in the introduction of legal cannabinoid pharmacotherapy in the regions of Ukraine to assist seriously ill citizens.
Essence of Prescription and Medical Indications
Medicines based on medical cannabis are prescribed by specialized professionals to provide quality symptomatic therapy and manage chronic pain syndrome. As representatives of the Mykolaiv Regional Council emphasize, such drugs are used not only in oncology but also for neurological diseases, severe injuries in military personnel, and civilians. The main difference between legal drugs and illegal analogues is a clearly standardized composition, strictly controlled dosage, and a low content of the psychoactive substance — tetrahydrocannabinol.
Expert Opinions and the Role of the State
Head of the Mykolaiv Regional Council Anton Tabunshchyk emphasized that the introduction of these drugs requires the highest level of responsibility from medical and pharmaceutical personnel, as well as ongoing educational work with the public. Yaroslav Yashchuk, Deputy Director of 'Pharmacia', explained that precise dosing of isolated active components makes it possible to guarantee treatment effectiveness without unwanted side effects. State control over the circulation of drugs is ensured through a comprehensive electronic healthcare system that tracks the entire path of the medicine from the manufacturer to the final patient.
Benefits for Cancer Patients
Maksym Bezноsenko, Director of the Mykolaiv Regional Oncology Center, noted the key benefits of such drugs as part of supportive therapy. According to him, the introduction of cannabinoids significantly reduces patients' need for opioid analgesics and minimizes associated risks. In addition, the medicines help cope with nausea and vomiting during chemotherapy and radiation therapy, stimulate appetite, prevent physical exhaustion, reduce anxiety levels, and normalize patients' sleep.
Controversial Data
While official medical departments and regional center management report a successful start to the program and necessary training completed by doctors, certain concerns and discussions persist in society and expert circles. Some specialized experts and citizens express skepticism regarding the infrastructure's readiness for mass control over the circulation of such drugs, citing rooted social stereotypes and fears of abuse. Nevertheless, the first successful prescription issuances across the country, which began back in June 2026, prove the practical viability and demand for the adopted legislative mechanism.
